Galectin Therapeutics reported $1.88M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.13B 73M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Galectin Therapeutics GALT:US $ 1.88M 308K
Gilead Sciences GILD:US $ 1.36B 274M
Idera Pharmaceuticals IDRA:US $ 2.66M 261K
Intercept Pharmaceuticals ICPT:US $ 39.98M 10.02M
Merk MRK:US $ 2.42B 118M
Regulus Therapeutics RGLS:US $ 2.47M 423K
Vital Therapies VTL:US $ 4.07M 82K
YTE INCY:US $ 253.28M 43.69M